Catalyst
Slingshot members are tracking this event:
Summit's (SMMT) EZUTROMID Granted Rare Pediatric Disease Designation from FDA in Treatment of Duchenne Muscular Dystrophy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SMMT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rare Pediatric Disease Designation, Fda, Duchenne Muscular Dystrophy, Ezutromid
